What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone

References

• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, . Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–80
   PubMed Web of Science ®Google Scholar
• Curb JD, Prentice RL, Bray PF, . Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772–80
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, . Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673–84
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, . Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Wassertheil-Smoller S, Johnson KC, . Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425–34
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, . Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357–65
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47–53
   PubMed Web of Science ®Google Scholar
• Information derived by Bayer HealthCare from data provided by Wolters Kluwer Health, Source(R) Retail data; 2001–2008
   Google Scholar
• North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–55
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, . Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1–66
   Google Scholar
• Sturdee DW, Pines A; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302–20
   PubMed Web of Science ®Google Scholar
• Tremollieres F, Brincat M, Erel CT, . EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas 2011;69:195–8
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, . Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
   PubMed Web of Science ®Google Scholar
• Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457–63
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, . Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Canonico M, Bouaziz E, Carcaillon L, . Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 2008;93:3082–7
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227–31
   PubMed Web of Science ®Google Scholar
• Straczek C, Oger E, Yon de Jonage-Canonico MB, . Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495–500
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Conard J, . Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4:1259–65
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THrombo-Embolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–32
   PubMed Web of Science ®Google Scholar
• Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 2010;17:1122–7
   PubMed Web of Science ®Google Scholar
• Post MS, Christella M, Thomassen LG, . Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116–21
   PubMed Web of Science ®Google Scholar
• Oger E, Alhenc-Gelas M, Lacut K, . Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671–6
   PubMed Web of Science ®Google Scholar
• Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):11–17
   PubMedGoogle Scholar
• Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012; 15(Suppl 1):18–25
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861–6
   PubMed Web of Science ®Google Scholar
• Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:342
   PubMed Web of Science ®Google Scholar
• Arana A, Varas C, González-Pérez A, Gutiérrez L, Bjerrum L, García Rodríguez LA. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause 2006;13:730–6
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• Liu B, Beral V, Balkwill A, . Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337:a386
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010; 303:2355–41
   PubMedGoogle Scholar
• de Lauzon-Guillain B, Fournier A, Fabre A, . Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort. Diabetologia 2009;52:2092–100
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar